Tag archive for ‘Xarelto’
Johnson & Johnson: A Core Holding for the Long Haul
I have just written a report on JNJ in which I reiterated my Buy recommendation. I don’t see a vibrant world economy in the next few years that will reduce pressure on healthcare spending and I think that JNJ will probably show growth in operational sales and earnings for in-line businesses in the 3% […]
FDA Cardiovascular and Renal Advisory Committee Goes Against FDA View and Recommends Approval of Xarelto
The FDA had apparently slammed the door shut on approval of Johnson & Johnson’s Xarelto (rivaroxaban) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF). The FDA reviewer in his briefing papers to the committee had recommended that the product be given a Complete Response Letter (not approvable at this time). The reviewer did […]